Connect with us
In phase 3 trials, Pfizer and BioNTech's vaccine showed strong immune responses against influenza A and COVID-19 but failed to meet key objectives for influenza B....
BioNTech's revenues plummeted 78.1% in the first half of 2024, down to €316.3 million, due to decreased demand for Covid-19 vaccines and a seasonal sales lull....
BioNTech saw a sharp drop in profits, starting 2024 with a €315 million loss, down from a €502 million profit the previous year, and sales plummeting...
A week ago, BioNTech presented its billing forecasts for 2024, with the aim of reaching €3 billion. The figure represents a significant decrease in value compared...
BioNTech 's turnover in 2022 was €17.31 billion, which represented a decrease of 8.8%. By business segments, those from the marketing of medicines amounted to €17.2...
As vaccine sales for Novavax, Moderna, and BioNTech shift in line with a changing Covid-19 situation, the results are being felt in the stock markets. Here...
Gilead's peak revenue in Spain was in 2015 when the company had a turnover $1.15 billion (€978.5 million). Those figures were due to the commercialization of...
The most sensational news came, on December 7th, from the Tübingen headquarters of Curevac, when its CEO Franz-Werner Haas announced the upcoming application for approval of...
BioNTech CEO Sierk Pötting expects to be able to present the first data from the ongoing study on the efficacy of BNT162 at the end of...
Biotech companies around the world have entered the race to find a coronavirus vaccine. In view of the increasingly critical situation of the coronavirus pandemic, the...